Literature DB >> 19111635

Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.

Kodo Tomida1, Takayuki Hamano, Satoshi Mikami, Naohiko Fujii, Noriyuki Okada, Isao Matsui, Yasuyuki Nagasawa, Toshiki Moriyama, Takahito Ito, Enyu Imai, Yoshitaka Isaka, Hiromi Rakugi.   

Abstract

The role of 25-hydroxyvitamin D [25(OH)D] and fibroblast growth factor-23 (FGF-23) in chronic kidney disease-mineral and bone disorder (CKD-MBD) remains elusive in predialysis CKD patients. From the fact that FGF-23 suppresses bone mineralization in vitro and that 1alpha-hydroxylase is present in parathyroid cells and osteoblasts, they may be associated with bone mass or serum parathyroid hormone (PTH) level. In this cross-sectional observational study, we investigated the potential associations of 25(OH)D or FGF-23 with 1-84 PTH and bone mineral density (BMD) in the femoral neck (FN) and lumbar spine (LS) of 325 non-diabetic patients. All patients had stages 3-5 CKD and had never been treated with bisphosphonate, estrogen, or vitamin D. We measured bone-specific alkaline phosphatase (bone ALP), intact FGF-23 and 1-84 PTH in a third generation assay, and performed a multiple regression analysis for 1-84 PTH and BMD Z-score. In our cohort, 80.1% had 25(OH)D levels less than 30 ng/mL, and 4.1% had levels less than 15 ng/mL. A univariate analysis indicated a negative association for 25(OH)D with 1-84 PTH and bone ALP. A multivariate analysis showed that the significant determinants for 1-84 PTH were 25(OH)D, estimated glomerular filtration rate (eGFR), corrected calcium, serum calcitriol and phosphate. Intriguingly, the three former parameters had negative associations with 1-84 PTH while calcitriol had a positive association. While further adjustment of FGF-23 extinguished the positive association of phosphate and 1-84 PTH, there was absolutely no increase in the R2. With regard to the BMD Z-score, 25(OH)D and the body mass index were the significant common independent positive determinants for both FN and LS, whereas bone ALP was the negative determinant even though there was no correlation noted for 1-84 PTH, calcitriol, or FGF-23 with BMD. In addition, eGFR positively contributed to the Z-score only in FN. Therefore, despite a positive correlation between 25(OH)D and calcitriol, their contribution to the CKD-MBD appears to be different. Since the significant associations for 25(OH)D with 1-84 PTH and BMD were independent of serum calcitriol and bone ALP, this might imply that 25(OH)D has a direct effect on the parathyroid gland and bone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19111635     DOI: 10.1016/j.bone.2008.11.016

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  15 in total

1.  CKD-mineral and bone disorder: core curriculum 2011.

Authors:  Ranjani N Moorthi; Sharon M Moe
Journal:  Am J Kidney Dis       Date:  2011-10-21       Impact factor: 8.860

2.  Safety, tolerability and pharmacokinetic study of recombinant human parathyroid hormone [rhPTH (1-84)] in Chinese healthy volunteers.

Authors:  Qian Li; Jian Qiao; Jungang Deng; Tianshu Zeng; Piqi Zhou; Weiyong Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-08-07

Review 3.  Secreted klotho and chronic kidney disease.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

4.  Vitamin D and parathyroid hormone status in community-dwelling elderly patients with mild-to-moderate kidney impairment.

Authors:  Nipith Charoenngam; Sutin Sriussadaporn
Journal:  Int Urol Nephrol       Date:  2021-01-09       Impact factor: 2.370

Review 5.  Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug?

Authors:  Patrick H Biggar; Orfeas Liangos; Holger Fey; Vincent M Brandenburg; Markus Ketteler
Journal:  Pediatr Nephrol       Date:  2010-04-27       Impact factor: 3.714

6.  Vitamin D insufficiency and bone fractures in patients on maintenance hemodialysis.

Authors:  Cs Ambrus; Cs Almasi; K Berta; Gy Deak; A Marton; M Zs Molnar; Zs Nemeth; Cs Horvath; P Lakatos; M Szathmari; I Mucsi
Journal:  Int Urol Nephrol       Date:  2010-03-18       Impact factor: 2.370

Review 7.  Evaluation of fracture risk in chronic kidney disease.

Authors:  Pablo Antonio Ureña Torres; Martine Cohen-Solal
Journal:  J Nephrol       Date:  2017-04-06       Impact factor: 3.902

8.  A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.

Authors:  Sharon M Moe; Akber Saifullah; Robert E LaClair; Sohail A Usman; Zhangsheng Yu
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

9.  Vitamin D status and outcomes after renal transplantation.

Authors:  Frank Bienaimé; Delphine Girard; Dany Anglicheau; Guillaume Canaud; Jean Claude Souberbielle; Henri Kreis; Laure Hélène Noël; Gérard Friedlander; Caroline Elie; Christophe Legendre; Dominique Prié
Journal:  J Am Soc Nephrol       Date:  2013-03-28       Impact factor: 10.121

Review 10.  Bone mineral density in patients on maintenance dialysis.

Authors:  Csaba Ambrus; Adrienn Marton; Zsofia Klara Nemeth; Istvan Mucsi
Journal:  Int Urol Nephrol       Date:  2009-12-29       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.